UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)

Grant

Date/time Interval

  • August 17, 2018 - August 16, 2023
  • Awarded By

    Total Award Amount

  • 58980.00
  • Direct Costs

  • 45370.00
  • Sponsor Award Id

  • Contributor

  • Rocque M.D., Gabrielle   Investigator  
  • Stringer-Reasor M.D., Erica   Investigator